ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Biomea Fusion, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Announcement - On June 6, 2024, Biomea Fusion announced that the FDA placed a full clinical hold on its Phase I/II clinical trials for the investigational covalent menin inhibitor BMF-219 in type 1 and type 2 diabetes [2]. - The company will continue to collect ongoing safety and efficacy data during the clinical hold period [2]. Group 2: Market Reaction - Following the announcement of the clinical hold, Biomea Fusion's stock experienced a significant decline, falling by 63% on June 7, 2024 [8]. Group 3: Legal Action - The Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses, allowing affected investors to potentially receive compensation without upfront fees [7].